$0.57
13.88% yesterday
Nasdaq, Aug 11, 10:17 pm CET
ISIN
US79400X1072
Symbol
SLRX

Salarius Pharmaceuticals Inc Stock price

$0.57
-0.18 23.88% 1M
-1.24 68.54% 6M
-1.27 69.05% YTD
-1.61 73.88% 1Y
-47.67 98.82% 3Y
-223.43 99.75% 5Y
-71,499.43 100.00% 10Y
-74,749.43 100.00% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.07 13.88%
ISIN
US79400X1072
Symbol
SLRX
Industry

Key metrics

Basic
Market capitalization
$4.4m
Enterprise Value
$2.7m
Net debt
positive
Cash
$1.8m
Shares outstanding
2.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
72.6
Financial Health
Equity Ratio
50.0%
Return on Equity
-368.8%
ROCE
-9,469.0%
ROIC
-
Debt/Equity
1.8
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-5.7m | -
EBIT
$-5.7m | $-6.2m
Net Income
$-5.6m | $-19.5m
Free Cash Flow
$-4.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
38.5% | -
EBIT
38.6% | -9.1%
Net Income
37.6% | -248.8%
Free Cash Flow
60.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.3
FCF per Share
$-2.1
Short interest
32.1%
Employees
2
Rev per Employee
$0.0
Show more

Is Salarius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Salarius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:

Hold
50%
Sell
50%

Financial data from Salarius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.08 5.08
8% 8%
-
- Research and Development Expense 0.60 0.60
84% 84%
-
-5.68 -5.68
39% 39%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.68 -5.68
39% 39%
-
Net Profit -5.57 -5.57
38% 38%
-

In millions USD.

Don't miss a Thing! We will send you all news about Salarius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Salarius Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
29 days ago
HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain co...
Neutral
GlobeNewsWire
about one month ago
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that two animal studies recently published in peer-reviewed jou...
Neutral
GlobeNewsWire
4 months ago
Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer's extensive scientific knowledge and experience Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer's extensive scientific knowledge and experience
More Salarius Pharmaceuticals Inc News

Company Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.

Head office United States
CEO David Arthur
Employees 2
Founded 2014
Website salariuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today